FindTrial
Sign In

A study to understand the tolerability, utilitization pattern and effects of Minocycline oral formulation

Tolerability, Drug Utilization Pattern and Effectiveness of Minocycline Oral Formulations in India: A Real World Retrospective Study from Electronic Medical Records - MENTOR

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2023/08/056338
Enrollment
2200
Registered
2023-08-09
Start date
Unknown
Completion date
Unknown
Last updated
2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L80-L99- Other disorders of the skin and subcutaneous tissue

Interventions

Intervention1: NA: NA Control Intervention1: NA: NA

Sponsors

Sun Pharma Industries Ltd.
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients >=12 years of age Patients prescribed with oral minocycline formulations Patients with a minimum of 1 follow-up visit data from the index date (first prescription) of oral minocycline formulations

Exclusion criteria

Exclusion criteria: Patients not on oral minocycline treatment

Design outcomes

Primary

MeasureTime frame
Proportion of patients with adverse events during the period of treatment with minocycline oral formulationsTimepoint: Baseline, Follow up visit—

Secondary

MeasureTime frame
Drug utilization pattern of minocycline oral formulations. Proportion of patients with symptom resolution during the treatment period with minocycline oral formulations in acne.Timepoint: Baseline, Follow up visit—

Countries

India

Contacts

Public ContactMs Colette Pinto

Sun Pharma Laboratories Limited

Mukesh.Gabhane@sunpharma.com02243244324

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Aug 14, 2026